SEPT9

Freenome’s Multiomics Blood Test Shows Promising Results in Detecting Colorectal Advanced Adenomas in a Prospective, Multi-Center Clinical Study

Retrieved on: 
Tuesday, January 12, 2021

Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenomes multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs.

Key Points: 
  • Compared with the FDA-approved mSEPT9 (methylated septin 9) blood test, Freenomes multiomics blood test showed much higher sensitivity (41% vs. 22%)1 for detecting AAs.
  • That means with a blood test such as Freenomes multiomics test, not only can we detect colorectal cancer, but we may be able to prevent colorectal cancer altogether.
  • A blood test that can detect both advanced adenomas and early stage colorectal cancer could be an important tool in the fight against colorectal cancer.
  • Importantly, these new results also showed that Freenomes multiomics blood test detected twice as many advanced adenomas as cell-free DNA methylation-only or single-protein approaches.